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INTRODUCTION 
conditions of severe and moderate thrombocytopenia P16 P. In 
this study we want to show that IPM has potential clinical 
use in the treatment of bleeding due to thrombocytopenia.               
MATERIALS AND METHODS 
Preparation of IPM 
IPM is prepared from 8 outdated platelet units of Tehran 
Blood Transfusion Center. The units were pooled and 
centrifuged for 15 min at 1000 RPM to remove 
contaminating red cells and white cells. The supernatant 
was centrifuged for 30 min at 2500 RPM to remove 
plasma. The precipitate was resuspended in 25 ml 
physiological saline solution (0.9 g%). For lysis and 
disruption of platelets, freeze-thaw procedure was repeated 
three times at -80°C and room temperature for 6 and 2 h 
respectively. The solution was washed twice with 
physiological saline solution for removing of intracellular 
components by centrifugation (30 min at 2500 RPM). The 
precipitate was resuspended in 45 ml of the same solution. 
Pasteurization of sample 
The sample of IPM with 0.4 M sodium caprylate 
concentration was prepared and heated at 60°C for 20 h to 
inactivate possible viral or bacterial contaminants and 
formulated with sucrose 1 M and human serum albumin 
0.1% P17P.  
In vivo haemostasis assay 
The hemostatic activity of IPM was measured by bleeding 
time assay to correct prolonged bleeding time in 
thrombocytopenic rabbits. White New Zealand rabbits 3 to 
3.3 Kg in weight were made thrombocytopenic by 
subcutaneous administration of busulfan dissolved in 
polyethylene glycol 400 (15 mg/kg on Days 0 ,2, 4 and 6). 
We measured platelet count and bleeding time on Day 
Platelet transfusion is an effective therapy to control 
bleeding in thrombocytopenic patients. Unfortunately, 
blood platelet units are generally stored in blood banks for 
3-5 days, thereafter they are discardedP1-2 P.  For preserving 
platelets for a long period, a number of attempts have been 
taken to develop substitutes for platelets, as possible 
alternatives to currently available platelet concentrates. A 
number of studies have shown that platelet preparations 
with impaired metabolic or functional integrity still retain 
a certain degree of hemostatic propertyP3-6 P. Infusible platelet 
membrane (IPM) prepared from outdated human platelets 
have been developed as an alternative to standard platelet 
concentrates, with the additional advantage of long shelf 
life and increased viral safety and have confirmed useful in 
shortening bleeding time in rabbits with experimentally 
induced thrombocytopenia P7P.  
Platelet microparticles are  microvesicles of platelet 
membranes that form during the activation or mechanical 
disruption of plateletsP8P. They form spontaneously during 
platelet storage and can be detected in platelet 
concentratesP9-11 P, fresh frozen plasma and cryoprecipitate P12 P. 
They have properties of procoagulant activityP13P. Due to 
these microparticles have similar hemostatic properties as 
intact platelets, they can be considered as a strategy for the 
development of a platelet substitute. However, the earliest 
efforts of these preparations were not successful in vivo 
and produced considerable distress in experimental 
animalsP14P. With regard to this problem, The investigations 
postponed for nearly three decades until experiments in 
thrombocytopenic rabbits provided preclinical evidence of 
their hemostatic efficacy without significant morbidityP15P. 
IPMs consist of spherical vesicles with the modal diameter 
of approximately 0.6 μm and are composed of protein and 
phospholipids similar to that of platelets. IPMs enhance 
procoagulant activity at sites of vascular injury under  
ABSTRACT 
Several platelet substitutes have been used for transfusion in human and animal models. The potential hemostatic effect of 
infusible platelet membrane (IPM) was investigated for evaluation its ability to reduce the prolonged bleeding time in 
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of 2 mg per kg results considerable reduction in the bleeding time. The values of bleeding time in the 48 data sets were 
obtained. Decrease in the percentage of bleeding time elevation during 2, 4, 6 and 24 hours after injection in the test group of 
rabbits were found 24.8, 39.0, 52.4 and 95.6 respectively. Reduction in the bleeding time seen in our experimental animals may 
support clinical potential utility of IPM as a substitute for platelets in the treatment of thrombocytopenia in humans.     
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minute. The bleeding times was then measured at various 
times after injection, 2, 4, 6 and 24 hours. All bleeding 
time assays were performed in duplicate. 
RESULTS AND DISCUSSION 
In previous investigations bleeding time has been used to 
assessment of the hemostatic effectiveness of various 
agents in the rabbit model P18-20 P. In this study, we 
administered IPM at a dose of 2 mg per kg, to 
thrombocytopenic rabbits with platelet count of 50 to 70 
×10P3P per μL,  and we performed 48 sets of bleeding time 
measurements before of biosulfan injection, before and 2, 
4, 6 and 24R Rhours after IPM injection. The values of 
bleedingtime in these 48 data sets are summarized in Table 
1. 
 
7,9,11. Animals with 50-70 × 10 P3P per μL with prolonged 
bleeding time (≥7 min) were used in this assay. 
For bleeding time assay, a standard device (ITC Surgicut 
Bleeding time, Fisher Scientific Inc.) was used to provide 
uniform standardized incision depth in the ear (Incision 
D×L: 1.0 x 5.0 mm) with improved test standardization 
and reproducibility of bleeding time test results. We 
applied a Whattman filter paper to the flow of blood from 
the wound. A stopwatch was started immediately and 
every 30 seconds filter paper was used to draw off the 
blood. The time from when the incision was made until all 
bleeding has stopped was called the bleeding time. We 
determined the preinjection bleeding time in one ear and 
administrated IPM at a dose of 2 mg per kg by injection 
into the marginal vein of the other ear at a rate of 2 mL per  
Table 1: Results of bleeding time measurements during before biosulfan injection, before and after IPM injections 
in rabbits 
Bleeding* time 
(min) 
Before biosulfan 
injection 
Before IPM 
injection 
Time after IPM injection (hours) 
2 4 6 24 
Rabbit No 1 2.5 7.0 1.9 3.6 4.1 6.7 
Rabbit No 2 2.7 7.3 1.6 2.2 3.5 7.1 
Rabbit No 3 2.8 7.2 1.6 2.4 4.1 6.8 
Rabbit No 4 3.1 10.0 2.7 4.1 4.8 9.5 
Mean 2.8 7.9 2.0 3.1 4.1 7.5 
* Bleeding time was performed in duplicate and the mean was calculated 
chloride) to another group of rabbits, are summarized in 
Fig-1. For comparison of results, we expressed decrease in 
the percentage of bleeding time elevation after the 
administration of IPM to thrombocytopenic rabbits (Fig-1). 
As one can see from top curve in Fig-1, there is no 
significant change in the bleeding times of animals given 
excipient used in IPM formulation. Reduction in the 
percentage of bleeding time elevation during 2, 4, 6 and 24 
hours after injection in the test group of rabbits were found 
24.8, 39.0, 52.4 and 95.6 respectively (Fig-1). 
Because all the platelet counts in these animals are much 
lower than the normal mean value of 430 × 10P3P per μL, the 
bleeding times were considerably longer than the normal 
value of 1.7 minutes. In this study for reliability of the 
results, the bleeding time was measured in duplicate and 
the mean was calculated. 
The 10 sets of percentages of bleeding time elevations, and 
the corresponding data from 2 administrations of excipient 
(sucrose and human serum albumin in 0.9% siodium 
 
 
Hours after IPM injection 
Fig 1: Decrease in the percentage of bleeding time elevation after the administration of IPM to thrombocytopenic 
rabbits. The bleeding time was measured to a maximum of 15 minutes after 4 administrations of IPM at a dose of 2 
mg per kg and 2 administrations of excipient (sucrose and human serum albumin in 0.9% sodium chloride) 
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However, in this research, the bleeding time is used to 
determine the response in a group of rabbits, almost 
identical in age and weight, that are relatively healthy, 
though thrombocytopenic. The main point of this study is 
the change in the bleeding time during the early hours after 
the injection of IPM. An acceptable number of animals has 
been used, and the each assay was performed in duplicate. 
Our results indicate hemostatic effectiveness of IPM in this 
experimental setting. 
For possible usage of IPM as a drug in human and 
evaluation of its clinically significant consequences, 
human clinical trials should be performed in the future.    
CONCLUSION 
Reduction in the bleeding time seen in experimental 
animals may support clinical potential utility of IPM as a 
substitute for platelets in the treatment of 
thrombocytopenia in humans.  
 
The results of previous study was nearly similar to our 
study and has shown that administration of IPM (2 mg /kg) 
can shorten the prolonged bleeding time in 
thrombocytopenic rabbits at least 4 h after infusionP7P; 
however, in our study the maximum decrease in the 
percentage of bleeding time was observed at 2 h after 
infusion instead of 4 h.  In both studies this hemostatic 
effect was no longer detectable after 24 h of IPM 
administrations.  
The reduction of bleeding time in experimental animals in 
our study confirms the potential utility of IPM as a 
substitute for platelets in the treatment of 
thrombocytopenia in humans. The clinical utility of the 
bleeding time in clinical aspects is controversial. Many 
experts regard the bleeding time as useless, in that it does 
not predict surgical bleeding. Articles supporting this view 
are often presented by pathologists. Despite such articles, 
the bleeding time continues to be used by many clinicians, 
primarily surgeonsP21-25P. 
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